News

An Axovant Sciences therapy for Parkinson’s disease showed signs of effectiveness, but an Alzheimer’s treatment did not, according to separate Phase 2 clinical trials. Nelotanserin, the therapy candidate for Parkinson’s disease dementia (PDD) associated with hallucinations and for Dementia with Lewy Bodies (DLB), appeared safe as well as displaying signs of effectiveness,…

It’s widely accepted that Parkinson’s disease (PD) patients experience neuronal death in the brainstem. Now, for the first time, researchers report that the number of copies of mitochondrial DNA is increased in the surviving nerve cells within this area of the brain. Interestingly, specific brainstem neurons had more alterations in…

Adamas Pharmaceuticals is making a concerted effort to spread the word on its flagship treatment for the involuntary muscle movements that are a hallmark of Parkinson’s disease. The U.S. Food and Drug Administration approved Gocovri (amantadine) in August 17. Adamas began making the extended release capsules available in the United States in…

Low levels of blood caffeine and its metabolites may help identify patients with early Parkinson’s disease, according to new research. The findings are consistent with caffeine’s neuroprotective effects, previously observed in neurodegenerative diseases. The study, “Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease,”…

Even though 60 percent of Parkinson’s Disease patients develop psychotic symptoms, it was only in 2016 that a treatment for the condition was approved. Nuplazid (pimavanserin) employs an entirely different mechanism to control psychotic symptoms compared to the bulk of antipsychotic medications on the market. The review, “…

Deep brain stimulation (DBS) may help extend the survival of patients with Parkinson’s disease, according to a new study by researchers at the Edward Hines, Jr. VA Hospital in Hines, Illinois. “Overall, DBS surgery has been viewed quite positively by both patients and providers,” Dr. Frances Weaver, the study’s…

Deep brain stimulation (DBS) may be safe for Parkinson’s disease patients who have dementia, according to a small clinical trial by University College London scientists. The study, “Bilateral Deep Brain Stimulation of the Nucleus Basalis of Meynert for Parkinson Disease Dementia — A Randomized Clinical Trial,” was published…

Dutch researchers have developed laser shoes to help Parkinson’s patients overcome a brain disconnect that causes them to stop walking when they want to keep going. Lasers attached to each shoe give patients a visual cue of where they need to go. Without a visual cue, the brain disconnect often leads…

Denali Therapeutics says its experimental therapy for Parkinson’s disease, DNL201 — a small-molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) — stopped an average 90 percent of LRRK2 kinase activity at its highest concentration. When the drug’s levels dropped to the lowest concentration (known as trough levels), it still inhibited…

Throughout the past year, Parkinson’s News Today has brought you news on Parkinson’s disease treatment development, clinical trials, research, and events. As we look forward to bringing you more news in 2018, we would like to sum up 2017 by bringing you the Top 10 Parkinson’s disease stories that…